In a small double blind randomized control trial (pdf at link) at a Spanish hospital early administration of calcifediol (a Vitamin D metabolite) significantly cut ICU admission rate and was associated with a less severe clinical course.
Calcifediol (25-hydroxyvitamin D) is what the liver turns vitamin D3 into as a normal part of vitamin metabolism in a process that normally takes about 7 days. Calcifediol is what is actually tested for when testing a patient’s vitamin D3 levels. Calcifediol is further processed in the kidneys to make calcitriol which is the active form of vitamin D used by the body.
In the study patients who had a prior medical record of a vitamin D deficient test result within the one year prior to testing positive for COVID-19 were randomly assigned to receive the best standard of care (control group) or best standard of care and early administration of calcifediol (treatment group).
The treatment group had a far lower rate of rate of ICU admission and a less severe course of the disease.
The trial, run out of the Reina Sofia University Hospital in Córdoba Spain, only had 76 participants.
“Of 50 patients treated with calcifediol, one required admission to the ICU (2%), while of 26 untreated patients, 13 required admission (50 %) p value X2 Fischer test p < 0.001.”
The authors suggest a larger trial.